XSWXMOVE
Market cap2.38bUSD
Dec 20, Last price
106.40CHF
1D
0.00%
1Q
-9.22%
IPO
8.19%
Name
Medacta Group SA
Chart & Performance
P/E
47.94
P/S
4.45
EPS
2.37
Div Yield, %
0.52%
Shrs. gr., 5y
-0.05%
Rev. gr., 5y
13.38%
Revenues
511m
+16.85%
Net income
47m
+2.41%
CFO
75m
+2.20%
Dividend
May 10, 20240.55 CHF/sh
Earnings
Mar 11, 2025
Profile
Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Europe, North America, the Asia-Pacific, and internationally. It offers personalized kinematic models and 3D planning tools for use in hip, knee, shoulder, sports medicine, and spine procedures. The company was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 510,778 16.85% | 437,122 20.38% | 363,126 20.04% | ||||||
Cost of revenue | 435,721 | 368,304 | 295,571 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 75,057 | 68,818 | 67,555 | ||||||
NOPBT Margin | 14.69% | 15.74% | 18.60% | ||||||
Operating Taxes | 11,364 | 8,543 | 3,930 | ||||||
Tax Rate | 15.14% | 12.41% | 5.82% | ||||||
NOPAT | 63,693 | 60,275 | 63,625 | ||||||
Net income | 47,362 2.41% | 46,249 -10.23% | 51,521 38.90% | ||||||
Dividends | (11,054) | (10,418) | |||||||
Dividend yield | 0.44% | 0.51% | |||||||
Proceeds from repurchase of equity | (3,911) | 42,388 | (1,242) | ||||||
BB yield | 0.16% | -2.06% | 0.04% | ||||||
| Debt | |||||||||
Debt current | 55,034 | 12,981 | 69,490 | ||||||
Long-term debt | 187,697 | 165,325 | 70,736 | ||||||
Deferred revenue | 92,973 | 9,715 | |||||||
Other long-term liabilities | 69,467 | (137,592) | (49,552) | ||||||
Net debt | 221,939 | (55,207) | (47,005) | ||||||
| Cash flow | |||||||||
Cash from operating activities | 75,127 | 73,510 | 54,061 | ||||||
CAPEX | (71,239) | (63,158) | (46,491) | ||||||
Cash from investing activities | (80,606) | (65,106) | (52,042) | ||||||
Cash from financing activities | (10,130) | 3,438 | (31,212) | ||||||
FCF | (50,554) | (13,231) | (7,184) | ||||||
| Balance | |||||||||
Cash | 20,792 | 32,261 | 20,404 | ||||||
Long term investments | 201,252 | 166,827 | |||||||
Excess cash | 211,657 | 169,075 | |||||||
Stockholders' equity | 327,617 | 258,637 | 205,170 | ||||||
Invested Capital | 601,484 | 242,709 | 206,444 | ||||||
ROIC | 15.09% | 26.84% | 34.21% | ||||||
ROCE | 12.48% | 13.79% | 16.26% | ||||||
| EV | |||||||||
Common stock shares outstanding | 19,952 | 19,996 | 20,004 | ||||||
Price | 125.60 21.94% | 103.00 -27.46% | 142.00 62.10% | ||||||
Market cap | 2,505,964 21.67% | 2,059,584 -27.49% | 2,840,607 62.14% | ||||||
EV | 2,727,903 | 2,004,377 | 2,793,602 | ||||||
EBITDA | 132,708 | 111,945 | 102,829 | ||||||
EV/EBITDA | 20.56 | 17.91 | 27.17 | ||||||
Interest | 6,830 | 3,663 | 3,442 | ||||||
Interest/NOPBT | 9.10% | 5.32% | 5.10% | ||||||